Karuna

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

Retrieved on: 
Monday, February 5, 2024

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Catalent shareholders will receive $63.50 per share in cash in a deal with an enterprise value of approximately $16.5 billion.
  • Under the terms of the agreement, Everbridge will be acquired by Thoma Bravo for $28.60 per share in cash.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

Retrieved on: 
Tuesday, January 30, 2024

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Following the closing of the Merger, the combined company will be led by the Tectonic management team.
  • Under the terms of the agreement, California Bancorp will merge with Southern California Bancorp (Nasdaq - BCAL).
  • Specifically, each outstanding share of California BanCorp common stock will be exchanged for the right to receive 1.590 shares of Southern California Bancorp common stock.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

Retrieved on: 
Friday, January 26, 2024

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction.
  • Under the terms of the agreement, Carrols will be acquired by Restaurant Brands International Inc. (“RBI”) (NYSE: QSR).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

Retrieved on: 
Monday, January 22, 2024

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction.
  • Under the terms of the agreement, Carrols will be acquired by Restaurant Brands International Inc. (“RBI”) (NYSE: QSR).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

Retrieved on: 
Thursday, January 4, 2024

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $4.1 billion.
  • Under the terms of the agreement, RayzeBio stockholders will receive $62.50 per share in cash upon completion of the proposed transaction.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

Retrieved on: 
Tuesday, December 26, 2023

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $4.1 billion.
  • Under the terms of the agreement, RayzeBio stockholders will receive $62.50 per share in cash upon completion of the proposed transaction.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

MAPLIGHT THERAPEUTICS APPOINTS CHARMAINE LYKINS AS CHIEF COMMERCIAL OFFICER

Retrieved on: 
Tuesday, April 11, 2023

SAN FRANCISCO and BOSTON, April 11, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders, today announced the appointment of Charmaine Lykins, MBA, as chief commercial officer, effective April 3,2023.

Key Points: 
  • SAN FRANCISCO and BOSTON, April 11, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders, today announced the appointment of Charmaine Lykins, MBA, as chief commercial officer, effective April 3,2023.
  • "We are pleased to welcome Charmaine to our leadership team at this pivotal time for MapLight," said Chris Kroeger, M.D., MBA, MapLight's Chief Executive Officer and Founder.
  • "It's an exciting time to be joining MapLight and I am honored to work with this distinguished team of neuroscience research and development leaders," said Charmaine Lykins.
  • Ms. Lykins most recently served as Chief Commercial Officer at Karuna Therapeutics where she led planning and execution of the organization's commercial capabilities in preparation for the launch of KarXT.

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 20, 2023

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $400.0 million of its common stock.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $400.0 million of its common stock.
  • Karuna also intends to grant the underwriters a 30-day option to purchase an additional $60.0 million of its common stock.
  • All the shares in the proposed offering are to be sold by Karuna.
  • Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer

Retrieved on: 
Tuesday, December 6, 2022

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) and a member of the Companys board, effective January 3, 2023.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) and a member of the Companys board, effective January 3, 2023.
  • Mr. Meury will succeed Steve Paul, M.D., the current president, chief executive officer and chairman, who will transition to president of research and development and chief scientific officer and continue to serve as a member of the board following the effective date.
  • Most recently, Mr. Meury served as a partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry.
  • Prior to this role, he served as Allergans president, branded pharma, and executive vice president, commercial, North American brands.

Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference

Retrieved on: 
Tuesday, November 1, 2022

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. EST).

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. EST).
  • A live webcast of the presentation will be available on the Investor Relations page of Karunas website at investors.karunatx.com .
  • A replay of the webcast will also be archived for up to 30 days on Karunas website following the conference.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.